Lanadelumab to treat hereditary angioedema.

• Bettina Wedi ^[1]
  1. [1] Hannover Medical School

     Hannover Medical School

     Region Hannover, Alemania

     
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 55, Nº. 7, 2019 (Ejemplar dedicado a: Julio), págs. 439-448
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Lanadelumab is a human monoclonal antibody against plasma kallikrein indicated for prevention of attacksofhereditaryangioedema(HAE).HAEiscaused bySERPING1genemutationsresultingindecreasedor dysfunctional plasma protease C1 inhibitor (C1-INH) leading to a loss of inhibition of plasma kallikrein activity with subsequent cleavage of high-molecular-weight kininogen and release of bradykinin. There is a clear need for a non-plasma-derived, safe, effective and convenient prophylaxis of HAE attacks to reduce patients' daily burden of disease and disability. The percentage of patients who were attack-free for the last 16 weeks of a controlled study was 77% in the group receiving 300 mg lanadelumab every 2 weeks, compared with 3% with placebo. The most common side effects were mild injection-site reactions. Lanadelumab has the potential to change the approach from on-demand treatment to prophylaxis in HAE. Future studies will have to confirm long-term safetyandefficacyofprophylacticlong-terminhibition ofplasmakallikrein.